When end-market conditions erode, there's not a lot that even the best companies can do apart from hunker down, hold the line on costs and keep building for the future. So although I'm sure that those traders and investors who focus on the short term will think I'm nuts, I still happen to think that Agilent (NYSE:A) is a quality company and that today's valuation is pretty appealing for long-term holders.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Third Quarter Numbers Get Ugly Fast
Between Agilent's quarterly report and management's subsequent comments, it sounds like a lot of the company's end markets deteriorated further and faster than expected.

Revenue was up 2% as reported, down 2% in constant currency and up a bit more than 2% organic - well below the company's prior mid-single-digit guidance. Electronic measurement was down 1% from last year (flat organic) and down 4% sequentially. Chemical analysis was flat, as reported, up 3% organic and down 2% sequentially, while life sciences rose 2% as reported (5% organic) and fell 1% sequentially. The newly formed/reconstituted diagnostics and genomics segment saw 52% reported growth, with a 2% organic decline.

Margins don't look good, and objectively they weren't great, but I think they held up reasonably well overall. Gross margin fell by 70 basis points (both on a GAAP and non-GAAP basis), while operating income fell 4% on a reported basis, but rose 2% after stripping out items like acquisition costs.

SEE: Understanding The Income Statement

The Order Book - Things Are Tough out There
There's no question that conditions in many of Agilent's addressed markets have gotten more challenging. Orders fell 2% on an organic basis, resulting in a 0.96 book-to-bill. Every segment was down, with electronic measurement down on weak aerospace (defense) and industrial (autos and consumer electronics), while chemical analysis saw weakness in energy and petrochemicals. Given Danaher's (NYSE:DHR) comments regarding their test and measurement business, Agilent's experience doesn't seem out of the norm (the new norm, at least).

Life sciences was a little more encouraging. Big Pharma seems to be spending a little more, although academic markets are weak, and Agilent's sales there fell 6% this quarter. That's not going to be good news for Illumina (Nasdaq:ILMN), nor other life science tool and equipment vendors like Bruker (Nasdaq:BRKR), Thermo Fisher (NYSE:TMO) or Waters (NYSE:WAT).

Interestingly, Dako was pretty strong, with revenue up double-digits since Agilent's deal closed. As a reminder, Dako has solid share in pathology (particularly in areas like advanced staining) and is well ahead of Danaher and Abbott (NYSE:ABT) in that regard, but has stagnated due to a lack of product innovation. Although this quarter is encouraging, investors shouldn't get ahead of themselves on their expectations for Dako - the long-term potential is there, but as in the case of Danaher's purchase of Beckman, Agilent is going to have to invest time and money into Dako.

The Bottom Line
Agilent is a good company with solid brands, good market share and excellent returns on capital. However, it is not a perfect company; businesses like electronic test and measurement are not only cyclical, but the cycles are inconsistent and unpredictable. Agilent also doesn't always have the best reputation with all of its customers (some resent the money the company makes from service calls), though it seems that these customers continue to use and buy Agilent products anyway.


SEE: 5 Must-Have Metrics For Value Investors

I see no reason that Agilent cannot continue to grow its free cash flow at a healthy single-digit clip. That seems especially so when considering the emerging demand growth in markets like China, India and Brazil. With that sort of free cash flow production, fair value seems to lie in the mid-$50s which suggests that Agilent is not a bad stock to consider at these prices.



At the time of writing, Stephen D. Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  2. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  3. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  4. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  5. Stock Analysis

    Analyzing Sirius XM's Return on Equity (ROE) (SIRI)

    Learn more about the Sirius XM's overall 2015 performance, return on equity performance and future predictions for the company's ROE in 2016 and beyond.
  6. Stock Analysis

    Will Virtusa Corporation's Stock Keep Chugging in 2016? (VRTU)

    Read a thorough review and analysis of Virtusa Corporation's stock looking to project how well the stock is likely to perform for investors in 2016.
  7. Stock Analysis

    Analyzing Porter's Five Forces on JPMorgan Chase (JPM)

    Examine the major money-center bank holding firm, JPMorgan Chase & Company, from the perspective of Porter's five forces model for industry analysis.
  8. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  9. Stock Analysis

    Analyzing Dish Network's Return on Equity (ROE) (DISH, TWC)

    Analyze Dish Network's return on equity (ROE), understand why it has vacillated so greatly in recent years and learn what factors are influencing it.
  10. Fundamental Analysis

    5 Must-Have Metrics For Value Investors

    Focusing on certain fundamental metrics is the best way for value investors to cash in gains. Here are the most important metrics to know.
RELATED FAQS
  1. When does a growth stock turn into a value opportunity?

    A growth stock turns into a value opportunity when it trades at a reasonable multiple of the company's earnings per share ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center